Latest Recruitment News

Page 1 of 41
Xref Limited has launched strategic integrations with leading HR platforms Teamtailor and HiBob, aiming to accelerate its transition to a high-margin, API-driven revenue model and expand its global footprint.
Sophie Babbage
Sophie Babbage
18 Mar 2026
After an 18-month trading suspension, Lithium Energy Limited has resumed ASX trading, unveiling a diversified portfolio including new gold-copper and lithium brine projects alongside a strategic graphite acquisition.
Maxwell Dee
Maxwell Dee
17 Mar 2026
Neurotech International has opened the first clinical site for its pivotal Phase 3 trial of NTI164, targeting core symptoms of Autism Spectrum Disorder in children. This milestone marks a key step toward potential regulatory approval and commercialisation.
Ada Torres
Ada Torres
17 Mar 2026
Arovella Therapeutics has secured TGA confirmation to advance its Phase 1 trial of ALA-101 in Australia via the efficient Clinical Trial Notification pathway, following FDA clearance in the US.
Ada Torres
Ada Torres
16 Mar 2026
Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.
Ada Torres
Ada Torres
16 Mar 2026
Neurizon Therapeutics announces the resignation of CEO Dr Michael Thurn, with Executive Chair Sergio Duchini stepping in temporarily as the company embarks on a global hunt for new leadership.
Ada Torres
Ada Torres
16 Mar 2026
Aguia Resources has secured key mining concessions in Brazil, setting the stage for operational licensing and commissioning of its Tres Estradas phosphate mine by April 2026.
Maxwell Dee
Maxwell Dee
12 Mar 2026
Patrys has initiated manufacturing and regulatory steps for RLS-2201, its injectable Quetiapine formulation targeting delirium, aiming for Phase 0 trials in the second half of 2026.
Ada Torres
Ada Torres
11 Mar 2026
Dimerix Limited has completed dosing of the last adult patient in its ACTION3 Phase 3 trial for DMX-200, exceeding its recruitment target and setting the stage for key regulatory milestones.
Ada Torres
Ada Torres
10 Mar 2026
Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.
Ada Torres
Ada Torres
10 Mar 2026
LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.
Ada Torres
Ada Torres
5 Mar 2026
Nexalis Therapeutics has initiated its Phase 1 trial for IRX-616a, an inhaled cannabidiol treatment aimed at panic disorder, marking a significant step in developing rapid-onset anxiety therapies.
Ada Torres
Ada Torres
4 Mar 2026